INSIGHTS ON CLINICAL TRIAL PARTNERING

• Meeting Our Customers Real-World Data Needs

  Learn how Citeline generates insights from data and uses those findings to create not only dynamic dashboards but also ongoing patient recruitment programs.

• What Is Interactive Response Technology (IRT)?

  Learn how protocol-driven IRT systems support supply management and randomization to help trial teams cut risk and costs.

• Pay-By-Procedure Vs. Pay-By-Visit

  Explore how a pay-by-procedure model can reshape site payments, enhance transparency, and reveal meaningful efficiencies across complex clinical trials.

• How A Strategic Bioanalysis CRO Partnership Empowers Sponsors

  Choosing the right bioanalysis CRO is vital to avoid costly delays. Sponsors need evaluation strategies that prioritize proven quality, predictable timelines, and submission-ready data.

• Patient Centric Clinical Trials: Why Transportation Is A Timeline Risk

  2/24/2026

  Address transportation barriers to reduce protocol deviations and data gaps. Strategies that lower travel burden protect study timelines and improve visit adherence for better trial outcomes.

• Why Functional Outsourcing Is Important To Clinical Development

  8/1/2025

  Why is functional outsourcing important in today's clinical development environment, and where can you find scalable support that will flex with your changing needs?

• Why Your IRT/RTSM Vendor Relationship Matters More Than You Think

  3/25/2026

  Access how the quality of your RTSM vendor relationship shapes the day‑to‑day experience of clinical teams and why strong collaboration is essential for keeping studies running smoothly under pressure.

• When Your Protocol Includes Ocular Endpoints

  4/6/2026

  Standardizing ocular endpoint execution reduces participant dropout and eliminates data variability. Specialized oversight secures clinical timelines and ensures high-quality, submission-ready data.

• Creating Operational Efficiency And Competitive Edge

  9/10/2025

  Site networks offer a strategic approach to oncology clinical trials by accelerating study startup and expanding access to diverse patient populations.